Christine L. Phillips

Hematology | Oncology

3333 Burnet Ave
Cincinnati, OH 45229

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Discordant neoplasms in monozygotic twins with a germline RECQL5 variant.

Discordant neoplasms in monozygotic twins with a germline RECQL5 variant.

Journal: Cancer genetics

Published: May 24, 2026

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

Journal: Blood advances

Published: March 24, 2026

Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.

Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 25, 2026

CPX-351 in High-Risk Relapsed Pediatric Acute Leukemia: Real-World Phase 1 Data Establishing the FDA-Approved Dose.

CPX-351 in High-Risk Relapsed Pediatric Acute Leukemia: Real-World Phase 1 Data Establishing the FDA-Approved Dose.

Journal: Pediatric blood & cancer

Published: February 24, 2026

Emapalumab for Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CD19-Directed CAR-T in Two Patients With B-ALL: Clinical and Biomarker Correlates.

Emapalumab for Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CD19-Directed CAR-T in Two Patients With B-ALL: Clinical and Biomarker Correlates.

Journal: Pediatric blood & cancer

Published: January 22, 2026

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: January 14, 2026

Impact of Extramedullary Disease at Diagnosis on Outcomes Post Allogeneic Hematopoietic Cell Transplant in Children and Young Adults With Acute Myeloid Leukemia: A CIBMTR Report.

Impact of Extramedullary Disease at Diagnosis on Outcomes Post Allogeneic Hematopoietic Cell Transplant in Children and Young Adults With Acute Myeloid Leukemia: A CIBMTR Report.

Journal: Transplantation and cellular therapy

Published: November 06, 2025

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel.

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel.

Journal: Blood advances

Published: April 29, 2025

Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel.

Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel.

Journal: Blood advances

Published: April 14, 2025

Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry.

Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry.

Journal: Blood advances

Published: January 28, 2025

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy.

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy.

Journal: Blood advances

Published: September 20, 2024

Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study.

Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study.

Journal: Blood

Published: September 17, 2024

Showing 1-12 of 44

Last Updated: 09/26/2026